Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience

Author： Novitzky N Thomas V Hale G Waldmann H

ISSN： 1465-3249

Source： Cytotherapy, Vol.6, Iss.2, 2004-04, pp. : 172-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Innate immunity against hematological malignancies

By Ruggeri L Capanni M Tosti A Urbani E Posati S Aversa F Martelli MF Velardi A

Cytotherapy, Vol. 4, Iss. 4, 2002-07 ,pp. : 343-346

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Pharmacokinetics of CAMPATH-1H in BMT patients

By Rebello P Cwynarski K Varughese M Eades A Apperley JF Hale G

Cytotherapy, Vol. 3, Iss. 4, 2001-07 ,pp. : 261-267

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1H in the treatment of autoimmune cytopenias

By Marsh JCW Gordon-Smith EC

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 189-195

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1 antibodies in stem-cell transplantation

By Hale G Cobbold S Novitzky N Bunjes D Willemze R Prentice HG Milligan D MacKinnon S Waldmann H

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 145-164

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Impact on T-cell depletion and CD34⁺ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G

By Williams R.J. Clarke E. Blair A. Evely R. Hale G. Waldmann H. Brookes S. Pamphilon D.H.

Cytotherapy, Vol. 2, Iss. 1, 2000-01 ,pp. : 5-14

Ashgate Publishing Ltd

Access to resources Recommend Favorite